A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015/PRASINEZUMAB (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 6-YEAR ALL-PARTICIPANTS-ON-TREATMENT EXTENSION (PASADENA)

June 07, 2021
https://clinicaltrials.gov/ct2/show/NCT04777331
Neurology, Parkinson Disease
Principal Investigator: Peter A Le Witt, MD

Parkinson Disease, Movement Disorders, Roche

Open